

CLINICAL INFORMATION




RESPeRATE HIGHLIGHTS

RESPeRATE is the world's only FDA-cleared, non-drug, non-invasive hypertension treatment device. It offers a sustained BP reduction within a few weeks of use, and after close to one million "user-years," its only reported "side effect" is better sleep. RESPeRATE's safety and efficacy in lowering blood pressure have been demonstrated repeatedly in 20+ clinical studies published in peer-reviewed medical journals [2-20,22].

Below is a direct quote from the American Heart Association Scientific Statement "Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure" [1]:


"The overall evidence from clinical trials and meta-analysis suggests that device-guided slow breathing [RESPeRATE] can significantly lower blood pressure. There are no known contraindications to the use of the device and no adverse effects have been noted."

Results: 15 Studies



Office SBP change 4-8 weeks treatment
Weighted Mean -10 mmHg, 95% CI [-10.9, -8.9]

Home SBP Reduction within 8 Weeks [7]



PROVEN EFFICACY

Significant and sustained reduction in blood pressure (BP) within 8 weeks demonstrated when measured at the office [2-20], at home [3-7, 9, 12-13] and with 24-hour ABPM [4, 10, 17].

Across 15 published studies in patients with a mean baseline office SBP of 151 mmHg:

- Weighted average office BP reduction: -10/5 mmHg - adjunctive, on top of concurrent usual care of medication and lifestyle modification
- Populations ranged from prehypertension [13] to refractory hypertension [5]
- Included comorbidities such as diabetes [9, 11, 17], chronic kidney failure [18], gestational hypertension [20], pulmonary arterial hypertension, CHF, COPD, PTSD, and more - see full study list at resperate.com/clinical-proof
- Studies conducted in the U.S., Europe, Middle East, and Asia

CLINICAL INFORMATION




PROVEN EFFICACY CONTINUED

In a pooled analysis of 7 published studies, among patients with uncontrolled hypertension ($\geq 140/90$ mmHg), office BP decreased $-14/8$ mmHg versus $-9/4$ mmHg in active controls receiving usual care - a difference independent of gender and medication status ($p=0.008$) [21].


Greater reductions were observed for:

- Older patients: $16/7$ mmHg for age >65 [8]
- Higher baseline BP: $17/7$ mmHg for SBP >160 mmHg [8]
- More time spent in therapeutic slow breathing (<10 breaths/min) [6]
- Reductions were independent of gender and medications. [21]

For the complete list of RESPerATE 50+ clinical studies, including the comorbid conditions referenced above, please see resperate.com/clinical-proof.






HOW RESPeRATE WORKS



HOW IT OPERATES

RESPeRATE's Device Guided Breathing Technology guides users into therapeutic slow breathing with prolonged exhalation. The device analyzes each breathing pattern and composes, in real time, personalized inhale and exhale guiding tones that gradually lead the user below 10 breaths per minute.

After each session, normal breathing resumes, but the beneficial impact on blood pressure accumulates with routine use.



WHY IT LOWERS BLOOD PRESSURE

RESPeRATE's BP-lowering effect is explained by calming sympathetic neural activity [22–23], resulting in small-vessel dilation and a sustained decrease in peripheral resistance and arterial stiffness [14].

CLINICIANS FAQS

Which patients are good candidates for RESPeRATE?

RESPeRATE is suitable for patients with:

- Early or stress-related BP elevation (pre-hypertension, white-coat, anxiety-related)
- Medication challenges (side effects or reluctance to start therapy)
- Difficult-to-control hypertension (resistant cases or with relevant comorbidities)

Where can I find additional clinical information or professional support?

The QR code on the right, provides access to references and summaries of 50+ clinical trials, video overviews, and the option to schedule a Zoom session with our scientific support team.

What support do patients receive?

RESPeRATE comes with a structured program that helps patients stay on track with personal support, educational videos, BP tracking. A 90-day money-back guarantee is provided to ensure no financial risk for your patients.

Is there any administrative burden for my practice?

No. RESPeRATE requires no paperwork, no exchange of protected health information, and no administrative involvement from your staff.

Offer RESPeRATE in your practice



A growing number of clinicians offer RESPeRATE to their patients. See how at resperate.com/clinicians.

REFERENCES

- [1] Brook RD et al. Hypertension. 2013;61(6):1360–1383.
- [2] Schein MH et al. J Hum Hypertens. 2001;15(4):271–278.
- [3] Grossman E et al. J Hum Hypertens. 2001;15(4):263–269.
- [4] Rosenthal T et al. Am J Hypertens. 2001;14(1):74–76.
- [5] Viskoper R et al. Am J Hypertens. 2003;16:484–487.
- [6] Elliott WJ et al. J Clin Hypertens. 2004;6(10):553–559.
- [7] Meles E et al. Am J Hypertens. 2004;17:370–374.
- [8] Bae JH et al. Korean Hypertens J. 2006;1:19–23.
- [9] Logtenberg SJ et al. J Hypertens. 2007;25:241–246.
- [10] Aydin L et al. J Hypertens. 2008;26(Suppl 2):S371–S372.
- [11] Schein MH et al. J Hum Hypertens. 2009;23(5):325–331.
- [12] Altana MR et al. Blood Press. 2009;18:273–279.
- [13] Anderson DE et al. J Hum Hypertens. 2010;24:807–813.
- [14] Kim JH et al. J Korean Soc Hypertens. 2013;19:55–62.
- [15] Landman GW et al. JAMA Intern Med. 2013;173:1346–1350.
- [16] Hering D et al. J Hypertens. 2013;31:739–746.
- [17] Howorka K et al. Auton Neurosci. 2013;179:131–137.
- [18] Gusmão J et al. J Hypertens. 2012;30(Suppl):e141.
- [19] Wojcicki JM. High Blood Press Cardiovasc Prev. 2013;20(2):89–92.
- [20] El-Bandrawy AM et al. Physiotherapy Quarterly. 2023;31(3):36–40.
- [21] Elliott WJ, Izzo JL. MedGenMed. 2006;8(3):23.
- [22] Oneda B et al. Hypertens Res. 2010;33:708–712.
- [23] Harada D et al. Am J Physiol Heart Circ Physiol. 2014;307:H1159–H1168.